Thus, our findings reveal the opposite roles of CD4+ and CD8+ T cells in anti-PD-L1 therapy and suggest a potential new strategy to potentiate anti-PD-L1 therapy by remodeling tumor blood vessels in colorectal tumors. Here, CD8A is linked to neoplasm.